AbbVie Updates Previously Issued Q1 2024 Adjusted EPS Guidance From $2.30-$2.34 To $2.26-$2.30 Versus Consensus Of $2.35, Including $0.04/Share Dilutive Impact Related To The Immunogen Acquisition
Portfolio Pulse from Benzinga Newsdesk
AbbVie has revised its Q1 2024 adjusted EPS guidance downwards from $2.30-$2.34 to $2.26-$2.30, below the consensus of $2.35. This revision includes a $0.04/share dilutive impact from the acquisition of Immunogen.
February 12, 2024 | 12:45 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
AbbVie has lowered its Q1 2024 EPS guidance to $2.26-$2.30, below the consensus of $2.35, due to the Immunogen acquisition.
The downward revision of AbbVie's EPS guidance for Q1 2024, especially being below the consensus, is likely to negatively impact investor sentiment in the short term. The dilutive impact from the Immunogen acquisition indicates that the costs associated with this acquisition are significant enough to affect earnings per share, which can be a concern for investors looking for growth or stability in AbbVie's financial performance.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100